Published in BMC Biotechnol on November 23, 2011
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs (2014) 0.91
Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol (2015) 0.83
Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother (2012) 0.81
Human-like antibodies neutralizing Western equine encephalitis virus. MAbs (2014) 0.79
Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. PLoS One (2015) 0.79
A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C. BMC Biotechnol (2012) 0.78
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs (2015) 0.78
Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol (2015) 0.76
SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E. Toxins (Basel) (2017) 0.75
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods (1991) 4.34
Bacterial toxins: a table of lethal amounts. Microbiol Rev (1982) 3.74
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Hypersensitivity reactions associated with botulinal antitoxin. Am J Med (1980) 1.74
A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol (2001) 1.72
Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem (1996) 1.64
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun (1997) 1.56
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother (2007) 1.27
Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol (2009) 1.19
Botulism and vaccines for its prevention. Vaccine (2009) 1.18
Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother (2005) 1.17
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol (2008) 1.16
Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect Immun (1989) 1.15
A human scFv antibody generation pipeline for proteome research. J Biotechnol (2010) 1.13
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One (2008) 1.11
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem (2010) 1.09
Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods (2007) 1.07
On the influence of vector design on antibody phage display. J Biotechnol (2006) 1.07
Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J Proteomics (2008) 1.05
Analyzing the "degree of humanness" of antibody sequences. J Mol Biol (2007) 1.03
Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol (2008) 1.03
A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol (2004) 1.02
Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One (2010) 1.01
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol (2006) 1.00
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One (2009) 0.98
A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol (2006) 0.98
Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine (2009) 0.96
The humanness of macaque antibody sequences. J Mol Biol (2010) 0.96
Use of botulinum toxin in the neurology clinic. Nat Rev Neurol (2010) 0.95
A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs (2010) 0.93
Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem (2009) 0.90
Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol (1997) 0.85
A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine (2010) 0.82
A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res (2011) 0.80
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother (2007) 1.27
Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci (2003) 1.21
Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol (2009) 1.19
Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother (2005) 1.17
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol (2008) 1.16
Towards proteome scale antibody selections using phage display. N Biotechnol (2009) 1.15
A human scFv antibody generation pipeline for proteome research. J Biotechnol (2010) 1.13
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol (2013) 1.13
Minimum information about a protein affinity reagent (MIAPAR). Nat Biotechnol (2010) 1.10
On the influence of vector design on antibody phage display. J Biotechnol (2006) 1.07
Expression of recombinant antibodies. Front Immunol (2013) 1.06
Generating recombinant antibodies to the complete human proteome. Trends Biotechnol (2010) 1.04
Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol (2008) 1.03
Antibodies for biodefense. MAbs (2011) 1.02
A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol (2004) 1.02
Perspectives for systematic in vitro antibody generation. Gene (2005) 1.00
Phage display derived therapeutic antibodies. Curr Pharm Biotechnol (2008) 1.00
Rise and fall of an anti-MUC1 specific antibody. PLoS One (2011) 0.99
Lessons learned about pneumonic plague diagnosis from two outbreaks, Democratic Republic of the Congo. Emerg Infect Dis (2011) 0.99
Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) (2011) 0.99
SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. N Biotechnol (2008) 0.98
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One (2009) 0.98
Production systems for recombinant antibodies. Front Biosci (2008) 0.96
Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules (2011) 0.96
The humanness of macaque antibody sequences. J Mol Biol (2010) 0.96
The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern Lab Anim (2010) 0.95
New highly specific botulinum type C1 endopeptidase immunoassays utilising SNAP25 or Syntaxin substrates. J Immunol Methods (2009) 0.94
A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs (2010) 0.93
Improved microtitre plate production of single chain Fv fragments in Escherichia coli. N Biotechnol (2009) 0.92
Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One (2012) 0.92
Affinity maturation by phage display. Methods Mol Biol (2009) 0.91
External quality assessment for the determination of diphtheria antitoxin in human serum. Clin Vaccine Immunol (2010) 0.91
Transcutaneous immunisation assisted by low-frequency ultrasound. Int J Pharm (2008) 0.90
Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem (2009) 0.90
An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods (2008) 0.89
Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol (2014) 0.89
Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display. Appl Microbiol Biotechnol (2008) 0.88
A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem (2012) 0.87
Efficient production of soluble recombinant single chain Fv fragments by a Pseudomonas putida strain KT2440 cell factory. Microb Cell Fact (2011) 0.87
Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Biol (2008) 0.87
Development and comparison of two immunoassay formats for rapid detection of botulinum neurotoxin type A. J Immunol Methods (2007) 0.86
Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Vet Microbiol (2010) 0.86
Production of single chain Fab (scFab) fragments in Bacillus megaterium. Microb Cell Fact (2007) 0.85
Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display. BMC Biotechnol (2012) 0.85
Synthetic self-assembling clostridial chimera for modulation of sensory functions. Bioconjug Chem (2013) 0.85
Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis (2003) 0.85
Phage display-based identification and potential diagnostic application of novel antigens from Mycoplasma mycoides subsp. mycoides small colony type. Vet Microbiol (2009) 0.84
Suppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cells. PLoS One (2012) 0.84
TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci (2009) 0.84
Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J (2006) 0.84
Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol (2010) 0.83
Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol (2014) 0.83
Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect Immun (2006) 0.83
Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. J Immunol Methods (2009) 0.83
In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine (2004) 0.83
A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. Vaccine (2012) 0.82
In vitro antigen ELISA for quality control of tetanus vaccines. Biologicals (2012) 0.82
Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. J Biotechnol (2012) 0.82
Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. Infect Immun (2008) 0.82
Production of recombinant antibody fragments in Bacillus megaterium. Microb Cell Fact (2007) 0.82
Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. Eur J Immunol (2012) 0.81
Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmologica (2014) 0.81
Oligomeric forms of single chain immunoglobulin (scIgG). MAbs (2010) 0.81
Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay. J Pharm Biomed Anal (2010) 0.81
An immunochromatographic test for the diagnosis of ricin inhalational poisoning. Clin Toxicol (Phila) (2007) 0.81
Oligopeptide m13 phage display in pathogen research. Viruses (2013) 0.81
Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B. Clin Vaccine Immunol (2010) 0.81
Influence of the hydromechanical stress and temperature on growth and antibody fragment production with Bacillus megaterium. Appl Microbiol Biotechnol (2011) 0.80
Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine (2006) 0.80
On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm Res (2002) 0.80
Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs (2014) 0.80
The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs (2014) 0.80
A methodological approach to investigate steady state fucoxanthin chlorophyll a/c binding protein mRNA levels in Wadden Sea sediments. Int Microbiol (2003) 0.80
An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J Pharm Sci (2003) 0.80
Antibody production in Bacillus megaterium: strategies and physiological implications of scaling from microtiter plates to industrial bioreactors. Biotechnol J (2011) 0.78
Immune interaction between components of acellular pertussis-diphtheria-tetanus (DTaP) vaccine and Haemophilus influenzae b (Hib) conjugate vaccine in a rat model. Vaccine (2006) 0.78
Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: influence of network structure and drug size on release rate. J Biotechnol (2012) 0.78
Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J Control Release (2004) 0.78